Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Manuel Gentiluomo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0366-9653; OpenAlex author ID A5027597079. Sources: OpenAlex.

Their work

Papers
45 (first author 13, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
117
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 3 papers · 2020: 3 papers · 2021: 8 papers · 2022: 3 papers · 2023: 7 papers · 2024: 5 papers · 2025: 11 papers · 2026: 4 papers

Papers 45

  1. Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives. Co-author DOI 10.1016/j.dld.2026.03.002↗
  2. AISP position statement: Standardising biological sample collection and handling for advanced diagnostics and multi-omic analyses in pancreatic cancer. First author DOI 10.1016/j.dld.2026.08.021↗
  3. Vimentin expression as a prognostic marker in pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.3389/fmed.2026.1742644↗
  4. Correction: Vimentin expression as a prognostic marker in pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.3389/fmed.2026.1824707↗
  5. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  6. Genetic landscape for screening and early diagnosis of pancreatic ductal adenocarcinoma: is there a signature? First author DOI 10.1016/j.bpg.2025.101988↗
  7. Author's Reply: Comment on "Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarci… Co-author DOI 10.1016/j.dld.2024.12.025↗
  8. Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer. First author DOI 10.1016/j.semcancer.2024.12.005↗
  9. Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.02.009↗
  10. From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. Last author DOI 10.1016/j.semcancer.2025.03.004↗
  11. Genomic instability, DNA damage response and telomere homeostasis in pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.05.005↗
  12. Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors. Co-author DOI 10.1016/j.semcancer.2025.06.001↗
  13. Long or short? Telomere length and pancreatic cancer and its precursor lesions, a narrative review. Co-author DOI 10.1093/mutage/gead034↗
  14. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  15. Sex Disparities and Female Reproductive and Hormonal Factors Associated with Risk of Pancreatic Cancer in the European Prospective Investigation into Cancer an… Co-author DOI 10.3390/cancers17142275↗
  16. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  17. Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.10.015↗
  18. Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study. Co-author DOI 10.1093/bjsopen/zrad119↗
  19. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  20. Physical Activity, Sedentary Behavior, and Pancreatic Cancer Risk: A Mendelian Randomization Study. Co-author DOI 10.1210/jendso/bvae017↗
  21. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  22. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. First author DOI 10.1016/j.critrevonc.2023.104020↗
  23. Genetic and non-genetic risk factors for early-onset pancreatic cancer. First author DOI 10.1016/j.dld.2023.02.023↗
  24. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  25. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  26. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. First author DOI 10.1186/s40659-023-00457-y↗
  27. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression. Co-author DOI 10.3389/fonc.2023.1172606↗
  28. Germline genetic variability in pancreatic cancer risk and prognosis. Co-author DOI 10.1016/j.semcancer.2020.08.003↗
  29. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  30. In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration. Co-author DOI 10.3390/ijms23073775↗
  31. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. First author DOI 10.1002/ijc.33475↗
  32. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  33. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  34. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. First author DOI 10.1093/carcin/bgab057↗
  35. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. First author DOI 10.1136/jmedgenet-2020-106961↗
  36. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. First author DOI 10.1158/1055-9965.epi-21-0353↗
  37. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  38. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. First author DOI 10.3389/fonc.2021.771312↗
  39. Genome-wide association study identifies an early onset pancreatic cancer risk locus. First author DOI 10.1002/ijc.33004↗
  40. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. First author DOI 10.1136/jmedgenet-2019-106200↗
  41. Mitochondrial DNA Copy-Number Variation and Pancreatic Cancer Risk in the Prospective EPIC Cohort. Co-author DOI 10.1158/1055-9965.epi-19-0868↗
  42. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgz006↗
  43. Genetic variants in taste-related genes and risk of pancreatic cancer. Co-author DOI 10.1093/mutage/gez032↗
  44. Genetic polymorphisms in inflammatory genes and pancreatic cancer risk: a two-phase study on more than 14 000 individuals. Co-author DOI 10.1093/mutage/gez040↗
  45. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗

Closest collaborators

The 25 strongest of 117 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniele Campa · 21 shared papers, 2019–2025 · strength 3.76
  2. Federico Canzian · 14 shared papers, 2019–2025 · strength 1.98
  3. Giulia Peduzzi · 9 shared papers, 2019–2025 · strength 1.72
  4. Riccardo Farinella · 7 shared papers, 2023–2025 · strength 1.42
  5. Cosmeri Rizzato · 5 shared papers, 2023–2025 · strength 1.25
  6. Gabriele Capurso · 8 shared papers, 2019–2025 · strength 1.12
  7. Luca Morelli · 8 shared papers, 2020–2025 · strength 1.04
  8. Chiara Corradi · 5 shared papers, 2021–2025 · strength 0.98
  9. Silvia Carrara · 3 shared papers, 2023–2026 · strength 0.77
  10. Elisa Giovannetti · 3 shared papers, 2024–2026 · strength 0.67
  11. Oana Iulia Creţu · 2 shared papers, 2026 · strength 0.67
  12. Bogdan Silviu Ungureanu · 2 shared papers, 2026 · strength 0.67
  13. Cristian Virgil Lungulescu · 2 shared papers, 2026 · strength 0.67
  14. Claudio Luchini · 2 shared papers, 2026 · strength 0.66
  15. Francesca Tavano · 5 shared papers, 2019–2025 · strength 0.61
  16. Eithne Costello · 4 shared papers, 2019–2025 · strength 0.55
  17. Gregorio Di Franco · 3 shared papers, 2022–2025 · strength 0.49
  18. Pavel Vodička · 4 shared papers, 2019–2025 · strength 0.49
  19. Salvatore Paiella · 2 shared papers, 2025–2026 · strength 0.47
  20. Volkan N. Adsay · 2 shared papers, 2025 · strength 0.45
  21. Marco Calderisi · 2 shared papers, 2024–2025 · strength 0.42
  22. Stefano Crippa · 2 shared papers, 2023–2025 · strength 0.40
  23. Ye Lu · 3 shared papers, 2019–2020 · strength 0.39
  24. Lívia Archibugi · 3 shared papers, 2022–2025 · strength 0.37
  25. Annalisa Comandatore · 2 shared papers, 2024–2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.